ENERGÍA SOLAR TÉRMICA DE CONCENTRACIÓN

VolverVolver

Resultados 67 resultados LastUpdate Última actualización 26/01/2022 [08:49:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Página2 de 3 nextPage   por página


COMPUTATIONAL REDUCTION VACCINE FOR COVID-19 BIN100

NºPublicación: US2021403880A1 30/12/2021

Solicitante:

HANSON MATTHEW VERNON [US]

Resumen de: US2021403880A1

A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 100 base pairs or greater in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

traducir

FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION

NºPublicación: US2021403550A1 30/12/2021

Solicitante:

HUANG CAI GU [US]
MANGUKIYA HITESH BHAGAVANBHAI [CN]

WO_2022006051_A1

Resumen de: US2021403550A1

The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

traducir

MERS CORONAVIRUS VACCINE

NºPublicación: US2021401971A1 30/12/2021

Solicitante:

CUREVAC AG [DE]

US_2019351048_A1

Resumen de: US2021401971A1

The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.

traducir

BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN

NºPublicación: US2021403537A1 30/12/2021

Solicitante:

ABCLONAL SCIENCE INC [US]

Resumen de: US2021403537A1

Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.

traducir

DIAGNOSTIC DEVICE WITH DUAL-REGION SUBSTRATE

NºPublicación: US2021402398A1 30/12/2021

Solicitante:

DETECT INC [US]
DETACT INC [US]

WO_2021262978_A2

Resumen de: US2021402398A1

Described herein in an embodiment is a diagnostic device for detecting the presence of one or more target nucleic acids (e.g., a nucleic acid of a pathogen, such as SARS-CoV-2 or an influenza virus). In some cases, the diagnostic device comprises a substrate comprising both a reagent delivery region comprising one or more reagents (e.g., one or more nucleic acid amplification reagents) and a lateral flow assay region configured to detect one or more target nucleic acids. The substrate may be removably or permanently coupled to an inner component that is movable relative to an outer component. The diagnostic device may further comprise a sample-collecting component coupled to the outer component and/or the inner component. In some embodiments, the inner component may be moved relative to the outer component in order to sequentially expose the substrate to the collected sample. In some cases, the diagnostic device may be used with a reaction tube comprising one or more liquids (e.g., a reaction buffer) and/or a heating unit.

traducir

APPARATUS AND METHOD FOR POINT OF CARE, RAPID, FIELD-DEPLOYABLE DIAGNOSTIC TESTING OF COVID-19, VIRUSES, ANTIBODIES AND MARKERS, AUTOLAB 20

NºPublicación: US2021402392A1 30/12/2021

Solicitante:

AUTONOMOUS MEDICAL DEVICES INC [US]

Resumen de: US2021402392A1

An automated system communicated to a remote server for diagnostically field testing a sample taken from a patient using an automated portable handheld instrument to determine the presence of Covid-19 and/or antibodies thereto includes microfluidic circuits defined in a rotatable disk for performing a bioassay using a microarray to generate an electrical signal indicative of a bioassay measurement; the microarray operationally positioned in the microfluidic circuit; one or more lasers; one or more positionable valves in the microfluidic circuit; and a backbone unit for rotating the disk according to a protocol to perform the bioassay, for controlling the lasers to selectively open the positionable valves in the microfluidic disk, for operating the microarray to generate a digital image as a bioassay measurement; for communicating the bioassay measurement to the remote server, and for associating the performed bioassay and its corresponding bioassay measurement to the patient.

traducir

METHOD FOR INACTIVATING A VIRUS ON A SURFACE

NºPublicación: US2021402017A1 30/12/2021

Solicitante:

MERCK PATENT GMBH [DE]

Resumen de: US2021402017A1

The present invention is related to a method for inactivating a virus on a surface, especially in relation to a SARS-CoV-2 virus, to a composition capable of inactivating a virus on a surface as well as to the use of such a composition for the inactivation of a virus on a surface.

traducir

RAPIDLY DEPLOYABLE, COUGH AND SNEEZE, AEROSOL CONTAINMENT APPARATUS

NºPublicación: US2021402230A1 30/12/2021

Solicitante:

CAYCEDO CLAUDIO H [US]

Resumen de: US2021402230A1

A rapidly deployable, pressure sealed, cough and sneeze aerosol, containment apparatus to substantially eradicate the cold, the flu, and Covid-19.

traducir

METHOD AND APPARATUS FOR PERFORMANCE OF THERMAL BRONCHIOPLASTY TO REDUCE COVID-19-INDUCED RESPIRATORY DISTRESS AND TREAT COVID-19-DAMAGED DISTAL LUNG REGIONS

NºPublicación: US2021402218A1 30/12/2021

Solicitante:

AERWAVE MEDICAL INC [US]

US_11020618_B1

Resumen de: US2021402218A1

Apparatus and methods for deactivating pulmonary nerves extending along the main bronchi of a mammalian subject to reduce ARDS effects by advancing an ultrasound transducer into the right and subsequently left main bronchus. The ultrasound transducer emits circumferential ultrasound so as to heat a circumferential tissue volume encompassing the right and left main bronchus. The energy of <10 W acoustic for <5 sec will not be sufficient to cause tissue necrosis but sufficient to inactivate nerve conduction. This treatment can be performed without locating or focusing on individual pulmonary nerves.

traducir

Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers

NºPublicación: US2021402001A1 30/12/2021

Solicitante:

COHEN DAVID I [US]

WO_2022005644_A1

Resumen de: US2021402001A1

The present invention describes how a MAb specific to a viral or cancer antigen can be linked to a novel Zn porting peptide that is engineered to load ionic Zn absent requirement for biological catalysis, carry Zn stably through the circulation, release payload proximal to diseased cells, deliver its Zn cargo intracellularly due to ionophore activity, and release Zn intracellularly. As specifically designed for COVID-19, the payload can be released by furin cleavage, and the Zn released intracellularly by cleavage at a 3CL major COVID protease site replacing sequences naturally found in alpha defensin-5, as one example, or by many other variations encompassing this design. The peptide's entry and intracellular Zn release can be further facilitated by the insertion of an arginine-lysine rich membrane translocation sequence at its amino or carboxyl terminus. The design provides a novel unifying strategy for preventing and treating COVID-19 (SARS-CoV-2) infection, other coronaviral infections, influenza infections, and many cancers.

traducir

ANTI-VIRAL COMPOUNDS AND METHODS OF USING SAME

NºPublicación: WO2021262799A1 30/12/2021

Solicitante:

FLAGSHIP PIONEERING INC [US]

Resumen de: WO2021262799A1

Anti-viral compounds and methods of using antiviral compounds are described. The compounds can be used in methods of reducing infection rate of a virus and in methods of treating a viral infection in a subject in need thereof. The virus can be a coronavirus, such as SARS-CoV-2.

traducir

AN AUTOMATED QUANTITATIVE ASSAY DEVICE AND A METHOD OF PERFORMING THE QUANTITATIVE ASSAYS

NºPublicación: WO2021260666A1 30/12/2021

Solicitante:

STIMSON WILLIAM [GB]
ROTONDO DINO [GB]
COWAN DAVID [GB]

Resumen de: WO2021260666A1

The present invention relates to the field of assay devices and methods for performing assays, such as immunoassays. The system comprises a means to receive the target sample collected from a subject; a means to measure the target analyte possibly present in said target sample; and a process of measuring the target analytes in real time manner. The target analyte includes but is not limited to any biological analyte, microbial entity like those of viral or bacterial sources such as SARS-CoV-2. The invention thus primarily relates to measuring analytes of interest to detect and treat related indications, such as COVID-19.

traducir

BST-NEC DNA FUSION POLYMERASE FOR USE IN ISOTHERMAL REPLICATION OF SPECIFIC SARS COV-2 VIRUS SEQUENCES

NºPublicación: WO2021262013A1 30/12/2021

Solicitante:

GENEME SP Z O O [PL]

Resumen de: WO2021262013A1

The subject, of the invention is the Bst-Nec DIMA fusion polymerase for use in isothermal reproduction of specific sequences of the SARS CoV-2 virus.

traducir

MASK CASE

NºPublicación: WO2021259403A1 30/12/2021

Solicitante:

UENAL BERKAN [DE]

Resumen de: WO2021259403A1

The invention relates to a device for hygienically storing face masks. Because of the current pandemic in 2020, COVID-19, countries around the world are facing a great challenge. There is a requirement to wear mouth-and-nose protective masks in closed spaces (businesses, practices, etc.). Currently, the mouth-and-nose protective masks are stowed in jacket pockets or loose in purses, etc. In this way, dirt gets onto the protective masks and can then come in contact with the mouth and the nose. The invention is used for this purpose, the invention being storage bags/cases for mouth-and-nose protective masks. These are called "Maskenetui" (mask case) in German and "face case" in English. The inner compartment of the mask cases is made of transparent film or of high-quality aluminum foil. This characteristic allows the interior of the "mask cases" to be regularly disinfected and thus allows the mouth-and-nose protective masks to be stored hygienically. Using the principle of a snap closure, the protective masks can be removed and inserted with minimal finger contact. The invention lies in the field of cases/storage bags. The invention is used to hygienically store mouth-and-nose protective masks. Drawing: There are three sizes of the invention.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

NºPublicación: WO2021261993A1 30/12/2021

Solicitante:

UNTHREADT B V [NL]

Resumen de: WO2021261993A1

The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b.identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a va

traducir

Anti-microbial filter

NºPublicación: GB2596276A 29/12/2021

Solicitante:

ACELL IND LTD [IE]

WO_2021234086_A1

Resumen de: GB2596276A

A foam filter (5) for filtering air comprises an open-celled phenolic foam having an accessible pore volume of from 0.5 m3 to 0.96 m3 per m3 of foam, and further comprises an antimicrobial agent. The foam filter may form part of a laminated filter structure that includes at least one layer of additional material in contact with at least one surface of the foam filter. The foam filter or the laminated filter structure may form part of a system for the sanitisation of air. The system may comprise a chamber comprising one or more of the foam filters or laminated filter structures. Also claimed is a method of sanitising air with the system for the sanitisation of air, the use of the foam filter for killing microbes, such as SARS-CoV-2 and a kit for forming a chamber. The foam filter may effectively clean and sanitise circulating air so as to remove and/or kill microbes present in the air, thereby reducing the risk of infection spreading.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

NºPublicación: EP3928783A1 29/12/2021

Solicitante:

UNTHREADT B V [NL]

WO_2021261993_A1

Resumen de: WO2021261993A1

The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b.identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a va

traducir

DETERMINING THE IMPACT OF COVID-19 PROGRESSION

NºPublicación: EP3929937A1 29/12/2021

Solicitante:

BAYER AG [DE]

AUTOMATIC DETECTION OF COVID-19 IN CHEST CT IMAGES

NºPublicación: EP3929936A1 29/12/2021

Solicitante:

SIEMENS HEALTHCARE GMBH [DE]

US_2021398654_A1

Resumen de: US2021398654A1

Systems and methods for automatically detecting a disease in medical images are provided. Input medical images are received. A plurality of metrics for a disease is computed for each of the input medical images. The input medical images are clustered into a plurality of clusters based on one or more of the plurality of metrics to classify the input medical images. The plurality of clusters comprise a cluster of one or more of the input medical images associated with the disease and one or more clusters of one or more of the input medical images not associated with the disease. In one embodiment, the disease is COVID-19 (coronavirus disease 2019).

traducir

Food for auxiliary prevention or auxiliary treatment of COVID-19 and application thereof

NºPublicación: EP3928785A1 29/12/2021

Solicitante:

GUANGZHOU CENTURY CLINICAL RES CO LTD [CN]
GUANGZHOU XIN CHUANGYI BIOPHARMACEUTICAL CO LTD [CN]
GUANGZHOU WELMAN NEW DRUG R&D CO LTD [CN]
XIANGBEI WELMAN PHARM CO LTD [CN]
NANJING KANGFUSHUN PHARMACEUTICAL CO LTD [CN]

Resumen de: CN113304253A

The invention discloses application of lysozyme or a composition containing the lysozyme to preparation of food for auxiliary prevention or auxiliary treatment of COVID-19. The lysozyme or the composition thereof provided by the invention can effectively inhibit cell damage caused by new coronavirus, inhibit expression of inflammatory factors induced by the new coronavirus, improve airway obstruction and expiration volume reduction caused by lung lesions, and improve intestinal barrier dysfunction. The lysozyme or the composition has good effects on high virus load, respiratory distress, intestinal function impairment and the like of patients, and can reduce the new coronavirus infection rate and reduce the severe rate of COVID-19. In addition, due to the fact that the lysozyme is extremely high in safety, the lysozyme also has very important value for preventing COVID-19 of undiagnosed COVID-19 high-risk infected people.

traducir

USE OF ANTIDEPRESSANT AGENTS FOR TREATING THE COVID-19 DISEASE

NºPublicación: EP3928775A1 29/12/2021

Solicitante:

HOPITAUX PARIS ASSIST PUBLIQUE [FR]

MVA-BASED VACCINE AGAINST COVID-19 EXPRESSING SARS-COV-2 ANTIGENS

NºPublicación: EP3928789A1 29/12/2021

Solicitante:

CONSEJO SUPERIOR INVESTIGACION [ES]

ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION

NºPublicación: EP3928778A1 29/12/2021

Solicitante:

CROMIS LLC [RU]

Resumen de: RU2731932C1

FIELD: pharmaceutics.SUBSTANCE: invention refers to antiviral agents and concerns an anti-COVID-19 (SARS-CoV-2) viral pharmaceutical composition containing favipiravir which is presented in the form of film-coated tablets. Disclosed composition comprises: 43-44 % of micronised favipiravir with particle size of 40-50 mcm, 5.5-6.0 % sodium croscarmellose, 4.8-5.0 % povidone, 0.6-0.8 % magnesium stearate, 0.5-0.7 % of colloidal silica, 2.5-2.7 % of film shell and microcrystalline cellulose - the rest.EFFECT: said composition provides fast release of favipiravir from a dosage form (tablets).1 cl, 1 tbl, 3 ex

traducir

COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19

NºPublicación: US11207401B1 28/12/2021

Solicitante:

TEVOGEN BIO INC [US]

US_11219684_B1

Resumen de: US11207401B1

The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

traducir

Diagnostic test for vaccine validation and authentication and methods of use thereof

Nº publicación: US11209428B1 28/12/2021

Solicitante:

QUANTUM MAT CORPORATION [US]

Resumen de: US11209428B1

The present invention encompasses a diagnostic test and method to authenticate the veracity of a vaccine. The diagnostic test and method are especially useful in a specific and sensitive immunochromatographic assay, performable within about 15 minutes for the authentication, validation, and veracity of a vaccine, such as a COVID-19 vaccine, in a vial prior to administration to a human.

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver